NATIONAL PATENT JOINT VENTURE AIDS COMPOUND CLINICAL TRIALS
Executive Summary
NATIONAL PATENT JOINT VENTURE AIDS COMPOUND CLINICAL TRIALS will begin in the next four to six weeks, the company announced June 29. "Pursuant to an IND application filed with the FDA, the study, which is expected to commence in four to six seeks, is designed to test the effects of AS101 on approximately 30 AIDS patients," the release states. Scientific Testing Inc., a joint venture between National Patent Development and Bar Ilan University of Isreal, is the drug's sponsor. A proprietary synthetic compound, AS101 "has shown immuno-augmenting, antiviral and antitumor activity in preclinical animal testing and immuno-augmenting activity in a limited number of AIDS patients in Phase I foreign clinical tests," according to the release. "The clinical study will be conducted at the Institute for Immunological Disorders (M.D. Anderson Hospital) Houston, Texas, under the direction of Dr. Peter Mansell," the release notes. Previously, Mansell directed a trial of ICN's Virazole (ribavirin) in AIDS patients at that center. Other preliminary foreign trials testing AS101 against various cancers are either under development or have been started, National Patent added.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth